These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

957 related articles for article (PubMed ID: 26604682)

  • 1. Efficacy of trabectedin in advanced soft tissue sarcoma: beyond lipo- and leiomyosarcoma.
    De Sanctis R; Marrari A; Marchetti S; Mussi C; Balzarini L; Lutman FR; Daolio P; Bastoni S; Bertuzzi AF; Quagliuolo V; Santoro A
    Drug Des Devel Ther; 2015; 9():5785-91. PubMed ID: 26604682
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Danish experience with trabectedin treatment for metastatic sarcoma: Importance of hyponatremia.
    Schack LH; Mouritsen LS; Elowsson C; Krarup-Hansen A; Safwat A
    Acta Oncol; 2015 Jan; 54(1):34-40. PubMed ID: 25263179
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trabectedin for advanced soft tissue sarcomas: a single institution experience.
    Gounaris I; Hatcher HM; Davidson D; Sherbourne K; Alam S; Zaki KA; Horan G; Earl HM
    Future Oncol; 2014 Aug; 10(11):1843-51. PubMed ID: 24450573
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A retrospective analysis of antitumour activity with trabectedin in translocation-related sarcomas.
    Le Cesne A; Cresta S; Maki RG; Blay JY; Verweij J; Poveda A; Casali PG; Balaña C; Schöffski P; Grosso F; Lardelli P; Nieto A; Alfaro V; Demetri GD
    Eur J Cancer; 2012 Nov; 48(16):3036-44. PubMed ID: 22749255
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of trabectedin for the treatment of liposarcoma.
    Zijoo R; von Mehren M
    Expert Opin Pharmacother; 2016 Oct; 17(14):1953-62. PubMed ID: 27615729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trabectedin in advanced soft tissue sarcoma: case series.
    Demirci U; Buyukberber S; Yetisyigit T; Dizdar O; Benekli M; Alkis N; Coskun U;
    J BUON; 2012; 17(3):591-2. PubMed ID: 23033305
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial.
    Gronchi A; Ferrari S; Quagliuolo V; Broto JM; Pousa AL; Grignani G; Basso U; Blay JY; Tendero O; Beveridge RD; Ferraresi V; Lugowska I; Merlo DF; Fontana V; Marchesi E; Donati DM; Palassini E; Palmerini E; De Sanctis R; Morosi C; Stacchiotti S; Bagué S; Coindre JM; Dei Tos AP; Picci P; Bruzzi P; Casali PG
    Lancet Oncol; 2017 Jun; 18(6):812-822. PubMed ID: 28499583
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trabectedin in advanced uterine leiomyosarcomas: a retrospective case series analysis from two reference centers.
    Sanfilippo R; Grosso F; Jones RL; Banerjee S; Pilotti S; D'Incalci M; Dei Tos AP; Raspagliesi F; Judson I; Casali PG
    Gynecol Oncol; 2011 Dec; 123(3):553-6. PubMed ID: 21917307
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study.
    Grosso F; Jones RL; Demetri GD; Judson IR; Blay JY; Le Cesne A; Sanfilippo R; Casieri P; Collini P; Dileo P; Spreafico C; Stacchiotti S; Tamborini E; Tercero JC; Jimeno J; D'Incalci M; Gronchi A; Fletcher JA; Pilotti S; Casali PG
    Lancet Oncol; 2007 Jul; 8(7):595-602. PubMed ID: 17586092
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trabectedin in metastatic soft tissue sarcomas: Role of pretreatment and age.
    Hoiczyk M; Grabellus F; Podleska L; Ahrens M; Schwindenhammer B; Taeger G; Pöttgen C; Schuler M; Bauer S
    Int J Oncol; 2013 Jul; 43(1):23-8. PubMed ID: 23652821
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of trabectedin as an early treatment for advanced or metastatic liposarcoma and leiomyosarcoma.
    Blay JY; Casali P; Nieto A; Tanović A; Le Cesne A
    Future Oncol; 2014 Jan; 10(1):59-68. PubMed ID: 23987833
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I combination study of trabectedin and doxorubicin in patients with soft-tissue sarcoma.
    Blay JY; von Mehren M; Samuels BL; Fanucchi MP; Ray-Coquard I; Buckley B; Gilles L; Lebedinsky C; Elsayed YA; Le Cesne A
    Clin Cancer Res; 2008 Oct; 14(20):6656-62. PubMed ID: 18927308
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interruption versus continuation of trabectedin in patients with soft-tissue sarcoma (T-DIS): a randomised phase 2 trial.
    Le Cesne A; Blay JY; Domont J; Tresch-Bruneel E; Chevreau C; Bertucci F; Delcambre C; Saada-Bouzid E; Piperno-Neumann S; Bay JO; Mir O; Ray-Coquard I; Ryckewaert T; Valentin T; Isambert N; Italiano A; Clisant S; Penel N
    Lancet Oncol; 2015 Mar; 16(3):312-9. PubMed ID: 25680558
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trabectedin for Advanced Soft Tissue Sarcoma: Ten Year Real-Life Perspective.
    Shamai S; Merimsky O
    Isr Med Assoc J; 2018 Oct; 20(10):599-603. PubMed ID: 30324774
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trabectedin in patients with advanced soft tissue sarcoma: a retrospective national analysis of the French Sarcoma Group.
    Le Cesne A; Ray-Coquard I; Duffaud F; Chevreau C; Penel N; Bui Nguyen B; Piperno-Neumann S; Delcambre C; Rios M; Chaigneau L; Le Maignan C; Guillemet C; Bertucci F; Bompas E; Linassier C; Olivier T; Kurtz JE; Even C; Cousin P; Yves Blay J;
    Eur J Cancer; 2015 Apr; 51(6):742-50. PubMed ID: 25727882
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The safety and efficacy of trabectedin for the treatment of liposarcoma or leiomyosarcoma.
    Saponara M; Stacchiotti S; Gronchi A
    Expert Rev Anticancer Ther; 2016 May; 16(5):473-84. PubMed ID: 27043847
    [TBL] [Abstract][Full Text] [Related]  

  • 17. What makes real world outcomes in soft tissue sarcomas? A mono-institutional trabectedin experience.
    Moriceau G; Vallard A; Méry B; Rivoirard R; Langrand-Escure J; Espenel S; Ben Mrad M; Wang G; Diao P; Fournel P; Collard O; Magné N
    Bull Cancer; 2015 Oct; 102(10):814-22. PubMed ID: 26384694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules.
    Demetri GD; Chawla SP; von Mehren M; Ritch P; Baker LH; Blay JY; Hande KR; Keohan ML; Samuels BL; Schuetze S; Lebedinsky C; Elsayed YA; Izquierdo MA; Gómez J; Park YC; Le Cesne A
    J Clin Oncol; 2009 Sep; 27(25):4188-96. PubMed ID: 19652065
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trabectedin for inoperable or recurrent soft tissue sarcoma in adult patients: a retrospective cohort study.
    Angarita FA; Cannell AJ; Abdul Razak AR; Dickson BC; Blackstein ME
    BMC Cancer; 2016 Jan; 16():30. PubMed ID: 26786213
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of response evaluation criteria in solid tumours and Choi criteria for response evaluation in patients with advanced soft tissue sarcoma treated with trabectedin: a retrospective analysis.
    Taieb S; Saada-Bouzid E; Tresch E; Ryckewaert T; Bompas E; Italiano A; Guillemet C; Peugniez C; Piperno-Neumann S; Thyss A; Maynou C; Clisant S; Penel N;
    Eur J Cancer; 2015 Jan; 51(2):202-9. PubMed ID: 25499439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 48.